Stockreport

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

Monopar Therapeutics Inc.  (MNPR) 
PDF WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing [Read more]